A Tale of Two Bases: PermE8, WO6 and the Compounded Melasma Cream
Melasma management leans on a handful of actives, and several of them are fussy in water. That makes the base a real decision rather than a detail. This guide covers what the 2026 consensus papers recommend, what is FDA approved, why hydroquinone and ascorbic acid need the right vehicle, and what PCCA's PermE8 and WO6 are designed to do.
Dermatology preparations are compounded to a prescriber's specified actives and base in the non sterile lab at Mixwell Compounding Pharmacy in Chino, CA.
What melasma is and why the base matters
Melasma is a common acquired pigment disorder of sun exposed skin, most often the face, with several contributors including sun exposure, hormonal influences and genetic predisposition. It is also persistent, which makes planning for relapse part of management.
Because no single cause explains it, management combines sun protection, topical agents and sometimes oral therapy. The topical part is where compounding enters, and where the choice of base starts to matter.
Several of the actives prescribers reach for are chemically unstable in water, and the finished preparation has to stay potent for as long as the patient uses it. Our melasma and hyperpigmentation support page covers the clinical side. This guide covers the vehicle.
What the 2026 consensus papers say
Two recent expert consensus papers agree that sun protection is essential and that hydroquinone based triple combination cream is the leading topical option under supervision, but they differ on how long to use it.
| Consensus point | What the panel reported |
|---|---|
| Panel and method | The international Delphi consensus used 40 dermatologists from 11 countries. Of 34 statements, 21 reached high consensus, 4 moderate and 1 low. |
| Photoprotection | Daily broad spectrum sunscreen is essential, with UVA, UVB and visible light coverage. |
| First line topical | Regulated, supervised use of hydroquinone based triple combination cream is described as the gold standard. |
| Alternatives and additions | Azelaic acid, kojic acid, arbutin and vitamin C or E, with oral tranexamic acid as an adjunct or alternative. |
| Maintenance | The global consensus says maintenance is needed to preserve the response and prevent relapse, and that hydroquinone based triple combination should be avoided for maintenance. |
The same literature that names triple combination as the leading option also says it is not the tool for the long haul. A prescriber planning a course needs both statements in view, and so does anyone reading a beyond use date.
What is FDA approved
Tri-Luma, a prescription cream combining fluocinolone acetonide 0.01 percent, hydroquinone 4 percent and tretinoin 0.05 percent, is FDA approved for short term treatment of moderate to severe facial melasma alongside sun avoidance measures. Where it fits the patient, it is generally the appropriate first choice.
Hydroquinone itself changed status in 2020. Under the CARES Act, over the counter hydroquinone products were removed from the market as of September 23, 2020, and FDA states that there are no FDA approved or legally marketed over the counter skin lightening products. Hydroquinone remains available by prescription, including through compounding pharmacies.
Compounding becomes relevant when a prescriber wants a different strength, a combination that includes agents the consensus names such as kojic acid, azelaic acid or tranexamic acid, an excipient change for a patient who reacts to a commercial one, or a vehicle suited to the patient's skin. The section on what compounding adds explains why that rationale matters.
Why some actives are fussy in water
Hydroquinone and ascorbic acid are prone to oxidation, and oxidation is a concern when they are compounded in water containing bases. Oxidation can cost potency and change the color of the preparation.
That is the practical reason an anhydrous base is attractive for these actives. A base with water activity below 0.6 has very little free water to drive the breakdown. Our guide to anhydrous compounding bases explains water activity and how USP 795 uses it.
The vehicle also decides how the cream feels. A melasma regimen is used daily, often for weeks, on the face. A preparation that feels greasy or tacky is easy to skip, and a skipped application delivers nothing.
PermE8 and WO6 profiled
PermE8 and WO6 are PCCA anhydrous gel bases, both with water activity below 0.6, and each is built for a slightly different job. This is what PCCA reports about each.
WO6 Anhydrous Topical Gel
Topical • DermatologyPCCA describes WO6 as an elegant base for a variety of dermatologic and cosmetic applications. Its water activity is below 0.6, which gives it a prolonged default beyond use date and lets it accommodate actives that are unstable in water, such as hydroquinone and ascorbic acid.
PCCA states that WO6 preparations containing hydroquinone or ascorbic acid can be stored at room temperature, provided no aqueous ingredients have been added. It is smooth and creamy without a greasy or tacky residue. PCCA lists azelaic acid, hydroquinone and tretinoin among the common actives for WO6.
PCCA specifies WO6 for topical use only and recommends EMP jars for dispensing.
PermE8 Anhydrous Gel
Topical • Permeation enhancingPCCA describes PermE8 as a permeation enhancing base in a silky, smooth anhydrous system. With water activity below 0.6, it carries an extended default beyond use date, and it can hold several actives at once, including actives in salt form.
In PCCA's in vitro testing, PermE8 delivered ketoprofen comparably to Lipoderm and at roughly four times the level of Anhydrous Lipoderm. PCCA's product booklet lists dermatology among its uses.
PCCA's product literature lists dermatology formulas prepared in WO6 alone and in a combination of PermE8 and WO6. Which arrangement suits a given prescription depends on the actives, the strength of the preparation and the feel the prescriber and patient want.
The published PermE8 delivery comparison used ketoprofen, so it does not speak to how much hydroquinone or tretinoin crosses skin from any base. It is laboratory permeation data, not clinical evidence. We are also not aware of a published clinical comparison of PermE8 and WO6 in melasma, and nothing here claims that one outperforms the other.
Want to talk through which base suits the actives you are considering?
Call (909) 378-7301What a longer beyond use date means here
A preparation in an anhydrous base can carry a default beyond use date of up to 180 days under USP 795, and that date is a limit on how long the preparation may be used, never a recommendation for how long to treat.
The longer default means fewer refills, which is convenient for a patient on a long plan. It does not change the clinical picture. The approved triple combination is labeled for short term use, and the global consensus advises against hydroquinone based triple combination for maintenance.
Two practical rules also apply. The date cannot exceed the shortest expiration of any component, and adding an aqueous ingredient can raise water activity above 0.6 and move the preparation into a shorter category. Our guide to how compounding bases set beyond use dates walks through both.
Match the quantity you write to the course you intend, and let your prescriber's reassessment schedule, not the label date, set how long the cream continues.
What compounding adds and what it does not
Compounding can supply a strength, a combination, an excipient choice or a vehicle that a commercial product does not offer, but it cannot make an unapproved combination approved or show that it outperforms an approved one.
What compounding can do
- Prepare a strength between or beyond commercial options
- Combine agents the consensus names, such as kojic acid or azelaic acid
- Leave out an excipient a patient reacts to, where the formulation allows
- Use an anhydrous base for actives that are unstable in water
What it does not mean
- That the preparation is FDA approved
- That it works better than Tri-Luma
- That one base outperforms another clinically
- That a long beyond use date is a long course
One regulatory point deserves a plain statement. Under section 503A, compounding copies of commercially available drug products is restricted. A compounded preparation should differ from the approved product in a way the prescriber determines is clinically significant for the patient, such as strength, combination, dosage form or an excipient, and noting that reason on the prescription is good practice.
Safety information
Hydroquinone containing preparations carry real risks, including irritation and a permanent discoloration called ochronosis, so supervision and a defined plan matter.
FDA has received reports of serious problems from skin lightening products containing hydroquinone, including rashes, facial swelling and discoloration that may be permanent, a condition called ochronosis. FDA laboratory testing has also found high levels of mercury in certain skin lightening products, and advises consumers not to use over the counter skin lightening products. A patient who stops a prescribed preparation should not substitute an unregulated product bought online or imported.
Retinoid containing preparations are generally avoided in pregnancy, and melasma is itself common during pregnancy, so tell your prescriber if you are pregnant, may become pregnant or are breastfeeding before starting. Corticosteroid containing preparations can cause skin thinning, irritation and other local effects with prolonged use. Sun protection is part of the plan rather than an extra, since the consensus calls daily broad spectrum sunscreen essential. This list is not complete, and the prescriber determines suitability and duration.
Writing the prescription
List each active with its strength, name the base or write pharmacist's choice, and state the quantity per fill so it matches both the course you plan and the beyond use date.
- Write each active and its strength individually, and note the clinical reason if the preparation differs from a commercial product.
- Name the base, such as WO6 or a PermE8 and WO6 combination, or write pharmacist's choice and we will tell you which we used.
- State the quantity per fill and the number of refills, and your plan for reassessment and maintenance.
- Note pregnancy or breastfeeding status and any ingredient to leave out.
- Call (909) 378-7301 to confirm the formulation and the date it carries.
Related preparations we make include a hydroquinone, tretinoin, azelaic acid and hydrocortisone gel, a hydroquinone, niacinamide and ascorbic acid gel and a hydroquinone, kojic acid, hydrocortisone and tretinoin topical gel. For the wider picture, see our prescriber's guide to writing compounded prescriptions.
Serving prescribers in California
Mixwell Compounding Pharmacy is a PCCA member pharmacy in Chino, CA, performing non sterile compounding only. We work with dermatology and primary care prescribers across the Inland Empire, Los Angeles County and Orange County, and deliver across California.
- Chino
- Chino Hills
- Ontario
- Rancho Cucamonga
- Upland
- Pomona
- Diamond Bar
- Corona
- Riverside
- Eastvale
- Brea
- Fullerton
Common questions
What is in a compounded melasma cream?
There is no single formula. Prescribers commonly combine a tyrosinase inhibiting agent such as hydroquinone with other actives named in expert consensus, including tretinoin, a mild corticosteroid, kojic acid and azelaic acid, in a base chosen to keep them stable. The prescriber decides the actives and strengths.
Is a compounded melasma cream FDA approved?
No. Compounded preparations are not FDA approved. The FDA approved option is Tri-Luma, a prescription cream combining fluocinolone acetonide, hydroquinone and tretinoin, approved for short term treatment of moderate to severe facial melasma alongside sun avoidance measures. Where it fits the patient it is generally the appropriate first choice.
Can I buy hydroquinone over the counter in the United States?
No. Since September 23, 2020, over the counter hydroquinone products have not been legally marketed under the CARES Act. Hydroquinone remains available by prescription, including through compounding pharmacies, and FDA warns against unregulated skin lightening products, some of which contain mercury.
Why is hydroquinone compounded in an anhydrous base?
Hydroquinone and ascorbic acid are prone to oxidation in water containing bases. PCCA states that its WO6 anhydrous base, with water activity below 0.6, can accommodate them, and that WO6 preparations of these actives can be stored at room temperature when no aqueous ingredients are added.
What is the difference between PermE8 and WO6?
Both are PCCA anhydrous gel bases with water activity below 0.6. PCCA describes PermE8 as a permeation enhancing base that can hold several actives, and WO6 as an elegant base for dermatologic and cosmetic use, specified for topical use. PCCA lists dermatology formulas in WO6 and in a PermE8 and WO6 combination.
Does a 180 day beyond use date mean I should use the cream for 180 days?
No. The date is the last day the preparation should be used, not a course length. The global consensus advises against hydroquinone based triple combination for maintenance, and the approved triple combination is labeled for short term use. Your prescriber sets the duration.
Is sunscreen necessary with a melasma cream?
Yes. The 2025 international consensus called daily broad spectrum sun protection, including UVA, UVB and visible light coverage, essential for everyone with melasma, alongside any topical treatment.
Can a melasma cream be used during pregnancy?
Tell your prescriber if you are pregnant, may become pregnant or are breastfeeding before starting. Retinoid containing preparations are generally avoided in pregnancy, and melasma is itself common during pregnancy, so this conversation matters.
Does Mixwell accept insurance, and can I use an HSA or FSA?
Mixwell does not accept insurance. Compounded medications for people can generally be charged to an HSA or FSA account. Call (909) 378-7301 for pricing.
Key Takeaways
- Expert consensus calls daily broad spectrum sun protection essential and names hydroquinone based triple combination as the leading topical option under supervision.
- Tri-Luma is the FDA approved triple combination, labeled for short term use, and over the counter hydroquinone has been off the market since September 23, 2020.
- Hydroquinone and ascorbic acid are prone to oxidation in water, which is why PCCA's anhydrous WO6 base is built to accommodate them.
- PermE8 and WO6 both have water activity below 0.6, and a longer beyond use date is a limit on use rather than a recommended course length.
- Compounded preparations are not FDA approved, and prescribers should note the clinical reason when a preparation differs from a commercial product.
Sources
- Sarkar R, Desai SR, Sinha S, et al. Delphi consensus on melasma management by international experts and Pigmentary Disorders Society. Journal of the European Academy of Dermatology and Venereology. 2026;40(4):680-692. doi:10.1111/jdv.70066
- Passeron T, et al. Global consensus on the management of melanin hyperpigmentation disorders. Journal of the European Academy of Dermatology and Venereology. 2026. PMC13109754
- Tri-Luma (fluocinolone acetonide, hydroquinone, tretinoin) cream prescribing information.
- U.S. Food and Drug Administration. FDA works to protect consumers from potentially harmful OTC skin lightening products. fda.gov
- U.S. Food and Drug Administration. FDA warns consumers of skin products containing mercury and/or hydroquinone. fda.gov
- Hydroquinone. Medscape Drug Reference, noting availability through 503A and 503B compounding facilities. reference.medscape.com
- PCCA. WO6 Anhydrous Topical Gel product information and frequently asked questions. pccarx.com
- PCCA. PermE8 Anhydrous Gel and Anhydrous Family product information, and the PCCA exclusive bases booklet. pccarx.com
- United States Pharmacopeia. General Chapter 795, Pharmaceutical Compounding, Nonsterile Preparations, Table 4. Official November 1, 2023.
- U.S. Food and Drug Administration. Compounding and the FD&C Act, Section 503A.